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Split-liver transplantation has been proposed as an alternative to whole liver (WL) transplantation to expand the donor pool,
but studies comparing adult longterm outcomes between the 2 methods are conflicting and limited. This is the first Italian mul-
ticenter study that retrospectively analyzed 119 matched-pair recipients of whole and extended right grafts (ERGs) for longterm
survival outcomes. In the overall population, WL recipients showed higher patient survival at 1 (93% versus 73%), 5 (87% ver-
sus 65%), and 10 years (83% versus 60%) after transplantation compared with split-liver recipients (P< 0.001); graft survivals of
WL recipients were also superior at 1 (90% versus 76%), 5 (84% versus 57%), and 10 years (81% versus 52%) posttransplant
(P< 0.001). However, among the 81 matched pairs that survived the first posttransplant year, 5- and 10-year patient survivals
were 90% and 81% for split recipients and 99% and 96% for whole recipients, respectively (P5 0.34). The 5- and 10-year graft
survivals were also comparable: 87% and 77% for split recipients, and 86% and 82% for whole recipients (P5 0.86). Cox regres-
sion analysis identified donor age >50, donor-to-recipient weight ratio< 1, retransplantation status, and United Network for
Organ Sharing I-IIA status as risk factors for partial graft use. There were no significant differences in 5-year outcomes based
on center volume. In conclusion, we demonstrate that adult liver transplantation with ERGs can achieve longterm success com-
parable with that of whole grafts in appropriate patients but should be selectively used in patients with risk factors.
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There is an increasingly large gap between the number
of patients on the liver transplantation waiting list and
the number of available organs. This shortage has
spurred the development of technical variant methods
such as split-liver transplantation (SLT)—in which a
deceased donor liver is divided between 2 recipients,
conventionally an extended right graft (ERG) given to
an adult and a smaller left lateral segment (LLS) given
to a child—in an effort to increase the number of
available grafts. Despite its potential, the wider appli-
cation of SLT is limited to a number of factors such as
Abbreviations: BMI, body mass index; CI, confidence interval;
DRWR, donor-to-recipient weight ratio; ERG, extended right graft;
HAT, hepatic artery thrombosis; HCC, hepatocellular carcinoma;
HCV, hepatitis C virus; HH, high-volume whole and split-liver
programs; HL, high whole and low split-liver programs; HM, high
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suitable donor for splitting procedure and logistical
issues; the proportion of liver transplants using split or
other reduced-sized grafts has been reported at under
6% in both Europe and the United States in recent
years.(1-4)
SLT has been promoted primarily to benefit the
pediatric liver transplant candidates, as a solution to
the lack of suitable graft options for small recipients.
The introduction of SLT has decreased the pediatric
wait-list mortality(5-7) and achieved great levels of success
in pediatric patients.(8-11) On the other hand, the ERG is
a partial graft transplanted to adult recipients instead of a
whole liver transplantation (WLT). Whether SLT has
comparable outcomes with WLT in adults is still under
debate. Even though split grafts are from “ideal” deceased
donors, ERG has been considered a higher-risk graft due
to potential prolonged cold ischemia times and other
technical limitations. Multicenter registry data implicate
SLT as a risk factor for worse outcomes,(5,9,12) but a num-
ber of studies have found comparable rates of 1-, 3-, and
5-year patient and graft survival between the 2 meth-
ods.(1,3,8,9,13-18) Much less information is available on
SLT outcomes beyond this time frame, though single
centers using carefully selected donors and recipients have
achieved 10-year patient outcomes similar to WLT.(3,19)
Differences in the occurrence of postoperative complica-
tions are also poorly understood because complications
with SLT have been reported as higher in some stud-
ies(3,20) but comparable in others.(1,9,13,15,16,18)
A multicenter, longterm comparison of the outcomes
of SLT and WLT in Italian recipients has never been
reported. Our study is a retrospective matched-pair analy-
sis comparing adult recipients of whole livers (WLs) to
those of ERGs. This report, dating back to the first SLT
procedures in Italy, presents the longterm outcomes as
well as an analysis of donor and recipient clinical variables,
based on data from 12 centers throughout the country.
Patients and Methods
STUDY POPULATION
This study includes data from 12 of the overall 18 Ital-
ian centers that performed liver transplants between
1997 and 2001—including San Martino Hospital of
Genoa; Maggiore Hospital, Niguarda Hospital, and
Istituto Nazionale Tumori Hospital of Milan; the Uni-
versity Hospitals of Bologna; University of Udine;
University of Padua, Papa Giovanni XXIII Hospital of
Bergamo; Tor Vergata and Sapienza University Hospi-
tals of Rome; the Mediterranean Institute for Trans-
plantation and Advanced Specialized Therapies
(ISMETT) of Palermo. These centers performed over
90% of the splitting procedures and WLTs in Italy
during that time period. Pediatric liver transplantations
were performed in 3 out of 12 participating centers:
Milan Maggiore, Padua, and Bergamo.
The donor organs were allocated according to Italian
National Transplant Center policy. With the exception of
United Network for Organ Sharing (UNOS) I status
patients, who were part of a national allocation process,
donor livers were allocated on a regional basis. Within
each region, organs were assigned in rotation to the con-
stituent transplant centers, which then chose a recipient
from their waiting list according to UNOS status. The
assigned center, informed of potential pediatric recipients,
determined if a liver should be split. Then, the center
decided which partial graft they wanted to transplant:
ERG, LLS, or both; if only 1 of the 2 grafts was used by
the center, the remaining graft was reallocated following
the criteria above. If a graft could not be allocated within
the region, it was offered and allocated to a center in a dif-
ferent region. The splitting criteria adopted in Italy during
the study period have been previously described by the
authors(21); those included recipient (donor-recipient
body weight ratio, UNOS status) and donor characteris-
tics (liver function tests, hemodynamic, and metabolic
whole and medium split-liver programs; HR, hazard ratio; ICU,
intensive care unit; ISMETT, Mediterranean Institute for Trans-
plantation and Advanced Specialized Therapies; LL, low whole and
split-liver programs; LLS, left lateral segment; MELD, Model for
End-Stage Liver Disease; MM, medium whole and split-liver pro-
grams; PNF, primary nonfunction; PT, prothrombin time; SLT,
split-liver transplantation; UNOS, United Network for Organ Shar-
ing; WL, whole liver; WLT, whole liver transplantation.
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status), and liver macroscopic appearance. Age alone was
not an exclusion criterion.
During the study period, 125 conventional split-liver
procedures were performed in 101 adult and 24 pediatric
cadaveric donors. The liver was divided into a LLS (seg-
ments II and III) and an ERG (segments I plus
IV–VIII) as described in a previous report.(21) The 121
splitting procedures were performed in situ; in a heart-
beating, deceased donor; and the remaining 4 were
performed ex situ, at the recipient center. Also, 124
patients (3 adult, 121 pediatric) received an LLS graft,
and 125 (121 adult, 4 pediatric) received an ERG. One
LLS graft was not transplanted due to iatrogenic lesions.
Using data from the Italian National Transplant Cen-
ter, all adult WLT recipients transplanted between 1997
and 2001 in the enrolled centers were included in a pool
of potential controls. From this pool, a control WLT
recipient was matched 1:1 with each of the 121 adult
ERG recipients based on the following characteristics:
center SLT volume, recipient age, urgency of transplan-
tation, indication for transplantation, number of past
transplantations, and donor characteristics. An appropri-
ate WLT matched-control recipient was not found for 2
ERG recipients; these patients were excluded from the
study. Hence, our study focuses on 119 matched pairs,
each with 1 ERG and 1WLT adult recipient.
As this study aims to analyze the longterm out-
comes, we conducted separate analyses for the overall
population (n5 119) and for the matched pairs recipi-
ents surviving the first year after transplant, who were
defined as the longterm study group (n5 81; Fig. 1).
The study protocol received a priori approval by the
appropriate institutional review committee.
CLINICAL VARIABLES OF
INTEREST
From the donor records, sex, age, ABO blood group,
weight, length of intensive care unit (ICU) stay, cause
of death, and administration of amines were recorded.
Recipients’ variables including sex, age, ABO blood
group, weight, body mass index (BMI), donor-to-
recipient weight ratio (DRWR), UNOS status, wait-
list time, retransplantation status, indication for liver
transplantation, degree of ascites and portosystemic
encephalopathy, prothrombin time (PT), serum albu-
min, and serum total bilirubin levels were collected.
The following postoperative variables were recorded:
cold ischemia time, ICU stay time, total hospital stay,
immunosuppressive medication, patient and graft sur-
vival, cause of death, cause of retransplantation, follow-
up time, need for posttransplant dialysis, and presence of
primary graft nonfunction.
In order to evaluate the possible impact of centers’
volume of activity, liver transplantation programs were
stratified according to the number of WLTs (high
volume, >50 procedures; medium volume, 25-50 pro-
cedures; low volume, <25 procedures), and SLT (high
volume, >20; medium volume, 10-20; low volume,
<10) per year during the study period.
STATISTICAL ANALYSIS
Descriptive statistics were performed using Microsoft
Excel, testing for differences between the 2 patient groups
with a Student t test and chi-square test for continuous
and categorical variables, respectively. For all groups stud-
ied, patient and graft Kaplan-Meier survival curves were
generated with SPSS software, and the 2 groups were
compared with the log-rank test. Patient and graft surviv-
als were analyzed at 1, 5, and 10 years of follow-up for
the overall population and at 5 and 10 years for the long-
term study group. To find risk factors associated with
undergoing SLT in place of WLT, each of the patient
variables recorded were analyzed with univariate Cox
regression to estimate a hazard ratio (HR) for patient loss
and graft loss with 95% confidence intervals (CIs). For the
longterm group, patients who survived but required
retransplantations within the first postoperative year were
included in the Cox regression analysis of variables related
to longterm patient loss but excluded from the longterm
graft loss analysis sample. Multivariate Cox regression
analysis was then performed on significant risk factors
identified from univariate analysis to determine indepen-
dent predictors of patient and graft loss after adjusting for
covariables. A P value of< 0.05 was considered to be sta-
tistically significant.
ETHICS APPROVAL
This study was approved by the ISMETT and University
of Pittsburgh institutional review boards (IRRB/03/13).
Results
PREOPERATIVE AND
POSTOPERATIVE VARIABLES
A summary of the clinical variables for ERG and
WLT recipients in both the overall population and the
longterm study group is presented in Table 1.
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In the overall population, administration of amines
was higher for WL donors (P< 0.001). Recipient
BMI was lower for split-liver recipients (P5 0.003),
but there was no significant difference in DRWR
(P5 0.57). SLT donor/recipient pairs were more likely
to have identical ABO blood groups (P< 0.001). No
other variations between the 2 populations were statis-
tically significant.
In the longterm survival group, similar to the overall
population study group, the SLT group displayed less
donor administration of amines (P< 0.001), higher
BMI (P5 0.01), with no difference in DRWR
(P5 0.49), and more donor/recipient pairs with iden-
tical ABO blood groups (P5 0.006).
On the basis of transplant volume, the distribution
of the participating transplant programs is described in
Table 2. Preoperative and postoperative variables by
center volume for the overall study population and for
the longterm survival group can be found in Support-
ing Tables 1 and 2.
PATIENT AND GRAFT SURVIVAL
The median follow-up time for the entire population
was 88 months (range 1-167 months). Kaplan-Meier
survival curves for the entire population and the long-
term group are shown in Figs. 2 and 3, respectively.
In the overall population, WLT recipients showed
higher patient survival rates at 1 (93% versus 73%), 5
(87% versus 65%), and 10 years (83% versus 60%)
compared with split-liver recipients (P< 0.001). WLT
recipients had also superior graft survival rates com-
pared with ERG recipients at 1 (90% versus 76%), 5
(84% versus 57%), and 10 years (81% versus 52%;
P< 0.001).
In the longterm cohort, the patient survival rates at
5 (99% versus 90%) and 10 years (86% versus 81%)
were similar for patients receiving WLT and ERG
(P5 0.34). Also the graft survival rates in the WLT
and ERG at 5 (86% versus 87%) and 10 years (82%
versus 77%) were comparable (P5 0.86).
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FIG. 1. Selection process of the study population.
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TABLE 1. Donor and Recipient Clinical Characteristics in the Overall Population and in the Longterm Study Groups
Overall Population Longterm Study Group
ERG WL P Value ERG WL P Value
Donor variables
Age, years 32.46 16.9 31.8616.2 0.89 31.36 16.6 35.66 18.4 0.32
Weight, kg 64.76 17.0 68.3612.9 0.09 64.96 11.8 67.16 13.2 0.45
Sex, male 62.5 69.2 0.54 57.9 78.6 0.28
ICU stay, days 2.96 4.3 2.962.4 0.89 3.86 6.7 3.26 2.2 0.63
Cause of death* 0.003 0.03
Brain trauma 45.7 28 52.4 26
Brain hemorrhage 35.3 57 33.3 58.7
Polytrauma 9.5 11.2 9.5 11.1
Brain hypoxia 6.9 0.9 4.8 -
Suicide 1.7 0.9 - 2.1
Other 0.9 2 - 2.1
Amines <0.001 <0.001
None 50.4 18.5 54.6 18.7
Single 47.9 71.4 45.4 64.6
Double 1.7 10.1 - 16.7
Recipient variables
Age, years 49.66 11.4 50.5611.4 0.58 54.26 8.9 54.667.4 0.83
Weight, kg 70.56 48.9 70.5615.2 0.99 65.86 15.5 70.36 15.1 0.17
Sex, male 58.5 59.7 0.89 64.3 68.7 0.66
BMI, kg/m2 23.863.2 25.46 4.4 0.003 26.16 3.7 24.26 2.81 0.01
DRWR 1.26 1.6 1.160.2 0.57 1.06 0.31 1.16 0.33 0.49
ABO match
Identical 65.5 43.7 0.001 71.4 41.7 0.006
Compatible 34.5 52.2 0.009 28.6 54.2 0.02
Incompatible - 4.1 - 4.1
Primary disease 0.88 0.08
Viral 47.9 52.9 83.3 91.7
Tumor 14.3 10.9 16.7 4.1
Retransplantation 10.1 10.9 - -
Cholestatic 7.5 5.0 - -
Alcoholic 5.9 5.9 - -
Metabolic 1.7 4.2 - 2.1
Acute hepatitis 1.7 1.7 - 0
Other 10.9 8.5 - 2.1
UNOS status† 0.86 0.28
I-IIA 18.5 17.1 5.6 14
IIB-III 81.5 82.9 94.4 86
Waiting time, days 2316 238 2136217 0.61 2146 180 2586 254 0.43
Bilirubin, mg/dL 5.06 8.0 5.066.3 0.96 4.66 4.4 2.7462.4 0.03
PT, seconds 57.16 25.1 48.2623.4 0.06 58.76 20.3 50.56 20.3 0.25
Albumin, g/dL 3.26 0.8 3.360.5 0.74 3.26 0.5 3.16 0.5 0.45
Ascites† 0.35 0.94
Absent 46.8 50.1 51.6 47.6
Well-controlled 38.3 41.8 38.7 42.9
Poorly controlled 14.9 8.1 9.7 9.5
Encephalopathy‡ 0.63 0.88
Absent 62.8 66.1 71 64.3
Minimal 28.1 22.3 9.7 11.9
Manifest 9.1 11.6 19.3 23.8
Postoperative variables
Cold ischemia time, minutes 5266 143 5066147 0.32 5286 134 5256 159 0.94
ICU stay, days 13.76 18.4 10.6616.5 0.25 12.96 16.5 8.26 10.6 0.23
Dialysis after transplant 8.4 6.7 0.81 7.1 6.2 >0.99
PNF 6.7 4.2 0.57 7.1 4.2 0.66
Hospital stay, days 37.06 28.6 29.3622.7 0.05 33.66 25.2 27.26 18.7 0.25
Immunosuppression
Cyclosporine 53 60 0.36 52.4 52.1 >0.99
Tacrolimus 35 34 >0.99 35.7 43.7 0.52
NOTE: Data are given as mean6 standard deviation and percentage.
*Data available in 106 split-liver donors for overall study population. Data available in 62 split-liver recipients and in 76 WL recipients
for longterm study group.
†Data available in 103 split-liver recipients and in 105 WL recipients for overall study population. Data available in 73 split-liver
recipients and in 70 WL recipients for longterm study group.
‡Data available in 87 split-liver recipients and in 99 WL recipients for overall study population. Data available in 62 split-liver recipi-
ents and in 67 WL recipients for longterm study group.
By log-rank test, there were no significant differ-
ences in 5-year patient or graft survivals among partici-
pating centers according to their volume of activity
(Table 3).
PATIENT AND GRAFT LOSS
The causes of death and retransplantation are summa-
rized in Table 4. Out of 49 ERG recipients’ deaths, 17
(34.7%) patients died more than 1 year after transplan-
tation (51.76 34.4 months), whereas 15 (65.2%)
WLT recipients died in the long term, after an average
of 76.16 38.7 months. In both groups, recurrence of
primary disease—hepatocellular carcinoma (HCC) or
hepatitis C virus (HCV)—was the most common
cause of longterm death (35% for ERG versus 27% for
WLT recipients).
Among ERG recipients, the overall retransplanta-
tion rate was 23.5%, compared with 6.7% in the WLT
cohort (P< 0.001). In the longterm population, 9
(11.1%) ERG recipients were retransplanted mainly
due to biliary complications (44.4%), whereas 1 (1.2%)
WLT recipient was retransplanted after 104 months.
COX REGRESSION ANALYSIS
Among the overall study population, univariate analy-
sis identified the following significant risk factors for
graft loss: nonidentical versus identical ABO blood
group (HR5 2.74, P5 0.01), donor age> 50 versus
 50 years (HR5 1.64, P5 0.04), UNOS I-IIA status
versus IIB-III status (HR5 2.38, P5 0.002), and
retransplantation versus overall indication for trans-
plantation (HR5 2.13, P5 0.01). At multivariate
analysis, donor age >50 versus 50 years (HR5 1.03,
P5 0.005) was associated with higher risk of graft fail-
ure (Table 5).
At univariate analysis, patient survival was associated
with the following risk factors: UNOS I-IIA status
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FIG. 2. (A) Patient and (B) graft survival curves of the overall
study population.
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FIG. 3. (A) Patient and (B) graft survival curves of the longterm
study groups.
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TABLE 2. Distributions of the Participating Transplant
Programs According to Their Volume Activity
Volume of
activity
Number of
centers
Number of
grafts ERG WLT
HH 2 85 (36%) 61 24
HM 2 24 (10%) 12 12
HL 2 52 (22%) 10 42
MM 2 56 (24%) 27 29
LL 4 21 (8%) 9 12
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versus IIB-III status (HR5 2.19, P5 0.01), donor age
> 50 versus 50 years (HR5 1.57, P5 0.04), and
retransplantation versus overall indication for trans-
plantation (HR5 2.35, P5 0.006). Donor age> 50
versus 50 years (HR5 1.02, P5 0.02) indepen-
dently influenced patient survival according to multi-
variate regression analysis (Supporting Table 3).
For the longterm groups, DRWR over versus under
1 (HR5 0.34, P5 0.01) was found to be a risk factor
according to univariate analysis. Multivariate analysis
did not identify any independent risk factors for graft
loss (Table 6).
At univariate analysis, patient loss was associated
with donor age >50 versus 50 years (HR5 2.12,
P5 0.04) and DRWR over versus under 1
(HR5 0.33, P5 0.04). Multivariate analysis identified
only donor age >50 versus 50 years (HR5 1.05,
P5 0.04) as a risk factor for patient loss (Supporting
Table 4).
Discussion
The principal aims of our study were to compare long-
term outcomes between split and WLT, as well as
identify risk factors affecting longterm survival to
improve donor and recipient selection. The retrospec-
tive and multicentric nature of our study made it diffi-
cult to adjust for differences in SLT recipient selection
and management. Though there may be bias from spe-
cific center practices, the multicenter perspective offers
the advantage of more universal applications. The case
and control groups created by the matched-pair
method had only minimal and expected differences in
clinical variables, as addressed below.
The current study analyzes the very early experience
with SLT, including the first procedures performed in
Italy, drawing from multiple centers with varying levels
of experience. At the time of the study, adult living donor
liver transplantations (LDLTs) were not performed in
Italy yet, so the technique had not impacted the learning
curve of SLT. Recent case studies from Italian centers
have demonstrated comparable outcomes between SLT
and WLT,(17,18,22) supporting the existence of a learning
curve as established in other counties.(23,24)
An increase in SLT has the potential to provide
greater access to donor organs—specifically the LLS
graft—to pediatric recipients. Notably, wait-list mor-
tality is higher for infants than any other age.(25,26)
SLT has been demonstrated to achieve similar out-
comes to WLT and LDLT but, unlike LDLT, does
not place a donor at risk.(9,11)
TABLE 3. Log-Rank Test Comparing 5-Year Patient and
Graft Survivals Among Participating Centers, Stratified
According to Their Volume of Activity
Study Group
Log-Rank Value
5-Year Patient
Survival
5-Year Graft
Survival
Overall study population (n5 238) 0.0749 0.3197
ERG recipients (n5 119) 0.3144 0.3144
WLT recipients (n5 119) 0.2708 0.0992
Overall longterm group (n5 162) 0.1943 0.3822
ERG recipients (n5 81) 0.1494 0.1494
WLT recipients (n5 81) 0.7527 0.6651
TABLE 4. Causes of Death and Retransplantation in the Overall Population and in the Longterm Study Groups
ERG WLT
Total Within 1 Year After 1 Year Total Within 1 Year After 1 Year
Causes of death 49 (41.2) 32 (26.9) 17 (14.3) 23 (19.3) 8 (6.7) 15 (12.6)
PNF 4 (12.5) 4 (12.5) - - - -
Vascular complication 5 (10.2) 3 (9.4) 2 (11.8) - - -
Infection/sepsis 11 (22.4) 11 (34.4) - 3 (13) 1 (12.5) 2 (13.3)
Multiple organ failure 8 (16.3) 8 (25) - 3 (13) 3 (37.5) -
HCC recurrence 3 (6.1) 1 (3.1) 2 (11.8) - - -
HCV recurrence 4 (8.2) - 4 (23.5) 4 (17.4) - 4 (26.7)
Biliary complication - - - 1 (4.3) - 1 (6.7)
Other 11 (22.4) 5 (15.6) 6 (35.3) 10 (43.5) 4 (50) 6 (40)
Unknown 3 (6.1) - 3 (17.6) 2 (8.7) - 2 (13.3)
Causes of retransplantation 28 (23.5) 19 (16) 9 (7.6) 8 (6.7) 7 (5.9) 1 (0.8)
PNF 3 (10.7) 3 (15.8) - 2 (25) 2 (28.6) -
HAT 12 (42.9) 11 (57.9) 1 (11.1) 2 (25) 2 (28.6) -
Biliary complications 6 (21.4) 2 (10.5) 4 (44.4) - - -
Primary sclerosing cholangitis recurrence 1 (3.6) - 1 (1.1)
Others 4 (14.3) 1 (5.3) 3 (33.3) 3 (37.5) 3 (42.9) -
Unknown 2 (7.1) 2 (10.5) - 1 (12.5) - 1 (100)
NOTE: Data are given as n (%).
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Donor livers designated for splitting, as well as
potential recipients of split grafts, must meet criteria
concerning age, BMI, liver function, prior hospitaliza-
tions, and other factors.(2,27,28) Accordingly, SLT
donors are more likely to be hemodynamically stable,
thus not requiring administration of amines, and more
likely to have identical blood types to their recipients.
Also, ERG recipients would be expected to have a
lower BMI in order to attain a sufficiently high
DRWR; there should be no significant difference in
DRWR between the 2 groups, as was the case in our
study.
TABLE 5. Univariate and Multivariate Analysis of Risk Factors Affecting Graft Loss in the Entire Study Population
Risk Factor HR Standard Error z P Value 95% CI
Univariate analysis
Donor age>50 versus 50 years 1.64 0.39 2.09 0.04 1.03-2.60
Donor amine 0 mg/ml/kg versus 1.2 mg/ml/kg 0.75 0.26 20.84 0.40 0.39-1.47
ABO identical versus unidentical 2.74 1.1 2.53 0.01 1.25-6.01
DRWR over versus under 1 0.7 0.18 21.4 0.16 0.43-1.15
Cold ischemia time
<6 versus 6 hours 0.94 0.38 20.17 0.87 0.43-2.05
<7 versus 7 hours 1.08 0.3 0.27 0.79 0.62-1.87
<8 versus 8 hours 0.73 0.19 21.2 0.23 0.44-1.22
Recipient age>50 versus 50 years 0.87 0.21 20.58 0.57 0.55-1.38
Primary disease
Cholestatic versus overall 0.93 0.48 20.14 0.89 0.34-2.56
Alcoholic versus overall 0.66 0.39 20.7 0.48 0.21-2.10
Viral versus overall 0.76 0.18 21.16 0.25 0.47-1.21
Metabolic versus overall 0.37 0.38 20.98 0.33 0.05-2.68
Tumor versus overall 0.41 0.42 20.88 0.38 0.06-2.97
Retransplantation versus overall 2.13 0.64 2.52 0.01 1.18-3.84
Other versus overall 0.87 0.45 20.26 0.79 0.32-2.40
UNOS I-IIA versus IIB-III 2.38 0.67 3.1 0.002 1.38-4.12
Cyclosporine versus tacrolimus 0.9 0.23 20.42 0.67 0.54-1.49
Multivariate analysis
Donor age>50 versus 50 years 1.03 0.01 2.81 0.005 1.01-1.05
ABO identical versus unindentical 1.38 0.87 0.52 0.61 0.40-4.75
DRWR over versus under 1 0.92 0.31 20.25 0.79 0.48-1.77
UNOS IIB-III versus I-IIA 0.85 0.43 20.33 0.75 0.32-2.28
Primary disease
Retransplantation versus overall 2.21 1.24 1.41 0.16 0.73-6.63
TABLE 6. Univariate and Multivariate Analysis of Risk Factors Affecting Graft Loss in the Longterm Study Groups
Risk Factor HR Standard Error z P value 95% CI
Univariate analysis
Donor age>50 versus 50 years 2.08 0.78 1.95 0.052 1.00-4.33
Donor amine 0 versus 1.2 0.86 0.46 20.28 0.78 0.30-2.47
ABO identical versus unidentical 2.96 1.82 1.77 0.08 0.89-9.85
DRWR over versus under 1 0.34 0.15 22.48 0.01 0.15-0.80
Cold ischemia time
<6 hours versus 6 hours 0.75 0.55 20.39 0.69 0.18-3.17
<7 hours versus 7 hours 1.17 0.52 0.35 0.73 0.49-2.78
<8 hours versus 8 hours 0.86 0.35 20.39 0.69 0.39-1.89
Recipient age>50 versus 50 years 0.99 0.37 20.02 0.99 0.48-2.06
Primary disease
Cholestatic versus overall 0.55 0.56 20.58 0.56 0.07-4.09
Alcoholic versus overall 1.31 0.97 0.37 0.72 0.31-5.59
Viral versus overall 0.81 0.34 20.49 0.62 0.36-1.86
Metabolic versus overall 0.74 0.76 20.30 0.77 0.10-5.48
Retransplantation versus overall 3.31 3.40 1.17 0.24 0.44-24.7
Other versus overall 1.00 0.74 0.01 0.99 0.24-4.27
UNOS I-IIA versus IIB-III 1.87 1.02 1.15 0.25 0.64-5.42
Cyclosporine versus tacrolimus 0.82 0.32 20.52 0.60 0.38-1.76
Multivariate analysis
Donor age>50 versus 50 years 1.03 0.02 1.61 0.11 0.99-1.06
DRWR over versus under 1 0.5 0.26 21.32 0.19 0.18-1.40
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Our short-term results showed that recipients trans-
planted with ERG had inferior graft and patient sur-
vival rates compared with those who underwent WLT,
mainly due to multiorgan failure and sepsis, suggesting
these patients were likely not appropriate candidates
for partial grafts. Improvements in short-term out-
comes in more recent reports indicate much of this
procedure-specific risk may now be obsolete given pro-
gression along the learning curve.(27) Short-term out-
comes among patients in North Italian centers, many
of which are included in our cohort, have been exten-
sively analyzed by Cardillo et al.(5); accordingly, they
are not the principal focus of this study and are not dis-
cussed further here.
This report is one of the few multicenter studies
analyzing a large series and providing longterm results
as far out as 10 years after transplantation. The 5- and
10-year ERG patient and graft survival rates in our
longterm cohort were comparable to that of WLT and
consistent with survival rates published in other reports
of WLT outcomes.(1,5,6,9,16,19,20) Late deaths, unlike
early deaths, were most frequently related to recurrence
of primary disease, suggesting a distinct process war-
ranting separate analysis. Previous multicenter studies
have reported inferior outcomes to WLT in SLT
patients.(5,9,12) However, a recent meta-analysis
showed similar patient and graft survival comparing
right lobe SLT and WLT in adult patients, despite
higher vascular and biliary complications in the split-
liver recipients.(29)
Similar outcomes were achieved with a selected sub-
group of patients, advocating identification of a suit-
able SLT recipient may be the strongest contributor to
minimizing the risk of patient death and graft loss.
Our results suggest that the use of ERG should be
pursued in low-risk adult patients. Furthermore, more
recent single-center studies demonstrate favorable out-
comes with split grafts even with more liberal donor
and recipient selection.(19,29) Notably, transplantations
in our study were performed before the introduction of
the Model for End-Stage Liver Disease (MELD)
score as a priority criterion for organ allocation. A
recent study reported improved outcomes with split
grafts after the introduction of the MELD score in the
United States in 2002, suggesting a critical role of
MELD in proper SLT recipient selection.(30)
Because center volume did not predict 5-year
patient or graft survival, other explanations for varia-
tion between centers, such as SLT donor/recipient
selection and posttransplant follow-up care plans,
should be explored. The limited number of procedures
at low-volume centers did not allow the comparison of
individual center survivals. A total of 61 ERG proce-
dures (75% of the patients in our study with longterm
follow-up) were performed by the 2 transplant centers
defined as high-volume programs both for WLT and
SLT, showing that, at the beginning of the Italian
splitting experience, partial liver grafts were accepted/
performed mainly by high-volume transplant centers.
Low-volume centers were likely more cautious regard-
ing SLT recipient selection, which may have influ-
enced their outcomes.
The results of our study and subsequent SLT expe-
riences have been especially important in defining the
new Italian national liver allocation criteria, which now
redeem the shortcomings of an entirely MELD-based
system, adopted since 2003, by considering donor
characteristics and allowing for the potential assign-
ment of partial grafts to less acutely ill patients.(31)
Nowadays, the national allocation policy considers all
standard-risk donors below 50 years of age suitable for
SLT. Unless an adult with UNOS status 1 or
MELD 30 is on the waiting list, the LLS of a
deceased donor with such characteristics is offered for
pediatric liver transplantation. If the LLS is allocated
to a pediatric recipient, the ERG is then allocated to
the best-matching adult recipient based not only on
the MELD score, but also on the recipient clinical sta-
tus and the donor/recipient size-matching.(32)
Retransplantation status is another factor that can
influence a patient’s prognosis. In our study, the propor-
tions of recipients in each group undergoing
retransplantation were similar both to each other and
to reported proportions of liver transplants world-
wide.(33-36) Our results suggest retransplantation repre-
sented a significant risk factor for patient and graft loss.
The majority of early retransplantations were due to
hepatic artery thrombosis (HAT), which occurred
more frequently in the SLT group due to the fact that
the left hepatic artery and celiac trunk were left with
the LLS, while only the right hepatic artery was
included with the ERG, resulting in more difficult
arterial anastomosis in ERG recipients.(21) To mini-
mize the risk of thrombosis, taking these data into
account, the Italian split policy was recently revised so
that to divide the hepatic artery properly according to
donor and recipient anatomy rather than always keep-
ing the celiac tripod with the LLS.(32)
Biliary complications were a cause of retransplanta-
tion in the ERG group but did not impact patient sur-
vival. Interestingly, biliary complications caused
retransplantation in ERG recipients mainly after 1 year
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from transplantation. Diagnosing biliary complications
may be complex in SLT and, as demonstrated in pediatric
SLT recipients, early diagnosis and treatment with biopsy
or cholangiography in the setting of impaired liver func-
tion, even without biliary tree dilation, avoids late graft
failure secondary to biliary cirrhosis.(37) In our study, diag-
nosis and management of biliary complications—for
example, the use of T tubes—were different in each cen-
ter and thus were not analyzed. Patients requiring retrans-
plantation for biliary complications were clustered in 3
centers, suggesting this morbidity may be more a function
of postoperative care than graft choice. Importantly, more
recent series have demonstrated lower rates of vascular
and biliary complications and retransplantation in SLT,
with results comparable with those ofWLT.(17,19)
Our study identified risk factors associated with
patient and graft loss in ERG recipients, underscoring
the importance of adequate donor/recipient matching
for early graft and patient survival. With univariate
analysis, risk factors for early partial graft failure were
ABO mismatch, retransplantation, and DRWR< 1,
and those for early patient loss were UNOS I-IIA sta-
tus, retransplantation, and DRWR< 1. In particular,
we confirmed that UNOS I-IIA status, including
patients with acute liver failure and patients admitted
to the ICU with kidney failure or gastrointestinal
bleeding, as well as ABO incompatibility were widely
associated with worse transplantation outcomes, sup-
porting prudent use of SLT in these patients as docu-
mented in previous reports.(5,6,9,27,38)
With multivariate analysis, the only significant risk
factor impacting patient and graft survivals, both in
the short and long term, was donor age of >50 years.
Advanced donor age has previously been reported as a
risk factor, though some studies demonstrate successes
using livers from older donors.(5,27,28) However, there
is no established cutoff for advanced age, and long-
term data on this subject are scarce.(5,27,28) In our
series, 21 (17.6%) ERG recipients underwent trans-
plantation with grafts from donors over 50 years. The
use of such donors was mainly related to the presence
of very sick pediatric recipients on the waiting list.
Splitting grafts from older donors did not influence
the pediatric outcomes. As shown in a previous Italian
report,(17) adults transplanted with ERG had inferior
graft survival rates compared with patients receiving
whole grafts from donors over 50 years. This indicates
that risk factors may be additive and that accurate
assessment of their presence or absence is crucial for
appropriate selection of candidate ERG recipients.
Therefore, after those results, the new Italian splitting
allocation policy considers only cadaveric donors with
age 50 years.
In our series, patients with HCV receiving ERG
had similar outcomes to those transplanted with whole
grafts (data not shown), suggesting these patients can
have longterm success with partial grafts in the absence
of other recognized risk factors.(39,40) Thus, the trans-
plantations in this study were performed before the
newer direct-acting antiviral agents became available.
The lack of risk factor consistency across all study
groups indicates the cause of graft loss is likely multi-
factorial and is consistent with previous work reporting
that the effect of 1 risk factor can be minimized by
controlling others.(27) Therefore, the presence of only
1 risk factor above should not rule out the use of SLT.
In conclusion, SLT is still being explored as an alter-
native technique to expand the donor pool. Our multi-
center study, which represents one of the earliest
experiences with SLT, showed that ERG recipients
were at an increased risk for early mortality and graft
failure, though satisfactory longterm outcomes were
achieved in those surviving the first posttransplant year.
These results are mainly related to the SLT learning
curve in Italy, where the use of partial grafts has pro-
gressively increased, especially in combined adult and
pediatric transplant programs. Worse outcomes were
associated with donor age> 50 years, DRWR< 1,
retransplantation, and recipient UNOS I-IIA status.
ERG use should be more selective in the presence of
these risk factors, especially in combination. Our results
support the 5- and 10-year efficacy of ERG transplan-
tation in appropriately selected adults and have helped
define a novel national allocation program to safely
increase sources of viable split grafts in the current era
of organ shortage.
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